|
Video: What is a Stock Split?
|
|
Statera Biopharma is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Co.'s proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia. Co.'s product candidate in this field is entolimod, an immune-stimulatory agent, which Co. is developing as a radiation countermeasure and other indications in radiation oncology. According to our STAB stock split history records, STAB has had 0 splits. | |
|
STAB (STAB) has 0 splits in our STAB stock split history database.
Looking at the STAB stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into STAB shares, starting with a $10,000 purchase of STAB, presented on a split-history-adjusted basis factoring in the complete STAB stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/06/2014 |
|
End date: |
01/20/2023 |
|
Start price/share: |
$0.58 |
|
End price/share: |
$0.03 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-94.83% |
|
Average Annual Total Return: |
-28.81% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$517.39 |
|
Years: |
8.72 |
|
|
|
|
|